Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy
During pregnancy, 91% of PWWE experience a 275% change from nonpregnant baseline in lamotrigine clearance whereas the remaining PWWE experience little to no change. Nonpregnant baseline lamotrigine clearance was higher in both PWWE and NPWWE with the administration of oral estrogen-containing medications. Our results are of clinical importance as they indicate a subpopulation without the need for substantial dose changes during pregnancy and a source of potential difference across nonpregnant individuals.
Authors
- Angela K. Birnbaum (ORCID: https://orcid.org/0000-0002-3969-4906)
- Kimford J. Meador (ORCID: https://orcid.org/0000-0002-7471-882X)
- Yuhan Long (ORCID: https://orcid.org/0000-0001-6933-4082)
- Page B. Pennell (ORCID: https://orcid.org/0000-0003-0568-2795)
- Ashwin Karanam (ORCID: https://orcid.org/0000-0003-0654-5266)
Institutions
- University of Minnesota (US)
- University of Pittsburgh (US)
- Pfizer (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/phar.4640
- Citations
- 10
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 34.94
Funders
- National Institute of Neurological Disorders and Stroke
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development